Anjali Apte-Deshpande
Lead Scientific Tech Writer at Vaxart, Inc. - South San Francisco, California, US
Anjali Apte-Deshpande's Colleagues at Vaxart, Inc.
Anjali Apte-Deshpande's Contact Details
(650) 550-3500
United States
Vaxart, Inc.
Anjali Apte-Deshpande's Company Details
For two hundred years vaccines have been administered by intramuscular injection. Vaxart’s oral vaccine pills may change everything. Our vaccine pills act differently, by attacking invading pathogens in the places where they first enter the body: the mucosal areas, including the mouth, the nose and the gut. They are designed to trigger strong IgA and T-cell responses to repel and overwhelm the invading viral invaders. Vaxart has begun Phase II trials of its oral vaccine for Covid and for Norovirus– the only company in the world to reach this stage with a COVID-19 vaccine pill.